Primary surgery for ovarian cancer

European Journal of Surgical Oncology

Volumn 32, Issue 8, 2006, Pages 844-852

  Trope C ^a   Kaern, J ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cytoreductive surgery; Neoadjuvant chemotherapy; Ovarian cancer; Staging; Teaching hospital

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; AREA UNDER THE CURVE; ARTICLE; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG DOSE REGIMEN; FEMALE; HIGH RISK POPULATION; HUMAN; HYSTERECTOMY; INTERNET; MEDICAL LITERATURE; MEDLINE; OVARIECTOMY; OVARY CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

FEMALE; HUMANS; HYSTERECTOMY; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

EID: 33749155771     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2006.03.036     Document Type: Article

References (65)

1. Parkin D.M., Pisani P., and Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80 (1999) 827-841
2. Cancer in Norway 1998 (2001), Cancer Registry of Norway, Oslo
3. Pisani P., Parkin D.M., Bray F., and Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83 (1999) 18-29
4. FIGO Annual Report 2001. J Epidemiol Biostat 6 (2001) 1-184
5. Cancer in Norway 2001 (2004), Cancer Registry of Norway, Oslo
6. Engeland A., Haldorsen T., Tretli S., et al. Prediction of cancer mortality in the Nordic countries up to the years 2000 and 2010, on the basis of relative survival analysis: a collaborative study of the five Nordic cancer registries. APMIS Suppl 49 (1995) 81-83
7. Gatta G., Lasoto M.B., Verdecchia A., and EUROCARE Working Group. Survival of European women with gynecological tumors during the period 1978-1989. Eur J Cancer 34 (1998) 2218-2225
8. In: Benedet J.L., and Pecorelli S. (Eds). Staging classifications and clinical practice guidelines of gynecologic cancers by FIGO Committee on Gynecologic Oncology (Chairman Hextan YS Ngan) (2003), Elsevier
9. Buchsbaum H.J., Brady M.F., Delgado G., et al. Surgical staging of carcinoma of the ovaries. Surg Gynecol Obstet 169 (1989) 226-232
10. Zanetta G., Rota S., Chiari S., et al. The accuracy of staging: An important prognostic determinator in stage I ovarian carcinoma. A multivariate analysis. Ann Oncol 9 (1998) 1097-1101
11. Benedetti-Panici P., and Angioli R. Role of Lymphadenectomy in ovarian cancer. Best practice research. Obstet Gynaecol 16 (2002) 529-551
12. Leblanc E., Querleu D., Narducci F., et al. Surgical staging of early invasive epithelial ovarian tumors. Semin Surg Oncol 19 (2000) 36-41
13. Kolstad P., and Tropé C. Preservation of ovarian function in the treatment of epithelial and specialized malignant tumors of the ovary: Convegno internazionale su I tumori delle gonadi (1987), Monduzzi Editore S.p.a, Bologna, Italy 321-337
14. Benjamin I., Morgan M.A., and Rubin S.C. Occult bilateral involvement in stage I epithelial ovarian cancer. Gynecol Oncol 72 (1999) 288-291
15. Randall T.C., and Rubin S.C. Surgical management of ovarian cancer. Semin Surg Oncol 17 (1999) 173-180
16. Zanetta G., Chiari S., Rota S., et al. Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynecol 104 (1997) 1030-1035
17. Weinstein D., and Polishuk W.Z. The role of wedge resection of the ovary as a cause for mechanical sterility. Surg Gynecol Obstet 141 (1975) 417-418
18. Brown C.L., Dharmendra B., and Barakat R.R. Preserving fertility in patients with epithelial ovarian cancer (EOC): The role of conservative surgery in treatment of early stage disease. [abstract]. Gynecol Oncol 76 (2000) 249
19. DiSaia P.J., and Creasman W.T. Epithelial ovarian cancer. In: DiSaia P.J., and Creasman W.T. (Eds). Clinical and gynecological oncology (1993), CV Mosby, St. Louis 333-525
20. Bolis G., Colombo N., Pecorelli S., et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). GICOG: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Ann Oncol 6 9 (1995) 887-893
21. Klaassen D., Shelley W., Starreveld A., et al. Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: a National Cancer Institute of Canada Clinical Trials Group report. J Clin Oncol 6 8 (1988) 1254-1263
22. Vergote I.B., Vergote-De Vos L.N., Abeler V.M., et al. Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 69 3 (1992) 741-749
23. Walton L.A., Yadusky A., Rubinstein L., Roth L.M., and Young R.C. Stage II carcinoma of the ovary: an analysis of survival after comprehensive surgical staging and adjuvant therapy. Gynecol Oncol 44 1 (1992) 55-60
24. Young R.C., Walton L.A., Ellenberg S.S., et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 322 15 (1990) 1021-1027
25. Sevelda P., Gitsch E., Dittrich C., et al. Therapeutic and prognostic results of a prospective multicenter ovarian cancer study of FIGO stages I and II. Geburtshilfe Frauenheilkd 47 3 (1987) 179-185
26. Tropé C., Kaern J., Hogberg T., et al. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann Oncol 11 3 (2000) 281-288
27. Trimbos J.B., Vergote I., Bolis G., et al. For the EORTC-ACTION collaborators. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 95 2 (2003)
28. International Collaborative Ovarian Neoplasm (ICON 1) Collaborators. International Collaborative Ovarian Neoplasm Trial 1: A randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 95 2 (2003)
29. International Collaborative Ovarian Neoplasm 1(ICON1) and European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant ChemoTherapy in Ovarian Neoplasm (EORTC-ACTION). International Collaborative Ovarian Neoplasm trial 1 and adjuvant ChemoTherapy in ovarian neoplasm trial: Two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 95 2 (2003)
30. Mok S.C., Chao J., Skates S., et al. Prostasin, a potential serum marker for identification through microarray technology. J Natl Cancer Inst 93 (2001) 1458-1464
31. Kristensen G.B., Kildal W., Abeler V.M., et al. Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer. Ann Oncol 14 10 (2003) 1494-1500
32. Petricoin E.F., Ardekani A.M., Hitt B.A., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 (2002) 572-577
33. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20 (2002) 1248-1259
34. Thigpen T. The if and when of surgical debulking for ovarian carcinoma. N Engl J Med 351 24 (2004) 2544-2546
35. Trimble E.L., Kosari C.A., Cornelison T.L., and Christian M.C. Improved survival for women with ovarian cancer. [abstract 324]. Gynecol Oncol 72 (1999) 522
36. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42 (1975) 101-104
37. Omura G.A., Bundy B.N., Berek J.S., Curry S., Delgado G., and Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 7 (1989) 457-465
38. Bristow R.E., Montz F.J., Lagasse L.D., Leucther R.S., and Karlan B.Y. Survival impact of surgical cytoreduction in Stage IV epithelial ovarian cancer. Gynecol Oncol 72 (1999) 278-287
39. Meigs J.V. Tumors of the female pelvic organs (1934), Macmillan, New York, NY
40. Hoskins W.J., Bundy B.N., Thigpen T.J., and Omura G.A. The influence of cytoreductive surgery on recurrence-free interval and survival in small volume stage 3 epithelial ovarian cancer: A Gynecologic Oncology Groups study. Gynecol Oncol 47 (1992) 59-66
41. Bristow R.E., Montz F.J., Lagasse L.D., Leuchter R.S., and Karlan B.Y. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 72 (1999) 278-287
42. Eisenkop S.M., Spirtos N.M., Friedman R.L., Lin W.C., Pisani A.L., and Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 90 (2003) 390-396
43. Chi D.S., Franklin C.C., Levine D.A., et al. Improved optimal cytoreduction rates for stage IIIc and IV epithelial ovarian cancer: Change in surgical approach. [abstract 42]. Gynecol Oncol 88 (2003) 175
44. Carter J. Primary surgery for ovarian cancer. In: Gershenson D.M., McGuire W.P., Gore M., Quinn M.A., and Thomas G. (Eds). Gynecologic cancer: controversies in management (2004), Elsevier 399-409
45. van der Burg M.E.L., and Vergote I. The role of interval debulking surgery in ovarian cancer. Curr Oncol Rep 5 (2003) 473-481
46. Rose P.G., Nerenstone S., Brady M.F., et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351 (2004) 2489-2497
47. Kumpulainen S., Grenman S., Kyyronen P., Pukkala E., and Sankila R. Evidence of benefit from centralised treatment of ovarian cancer: a nationwide population-based survival analysis in Finland. Int J Cancer 102 (2002) 541-544
48. Eisenkop S.M., Spirtos N.M., Montag T.W., Nalick R.H., and Wang H.J. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 47 (1992) 203-209
49. Junor E.J., Hole D.J., McNulty L., Mason M., and Young J. Specialist gynecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol 106 (1999) 1130-1136
50. Mayer A.R., Chambers S.K., Graves E., et al. Ovarian cancer staging: does it require a gynecologic oncologist?. Gynecol Oncol 47 (1992) 223-227
51. Junor E.J., Hole D.J., and Gillis C.R. Management of ovarian cancer: referral to a multidisciplinary team matters. Br J Cancer 70 (1994) 363-370
52. Kehoe S., Powell J., Wilson S., and Woodman C. The influence of the operating surgeon's sepcialisation on patient survival in ovarian carcinoma. Int J Cancer 70 (1994) 1014-1017
53. Woodman C., Baghdady A., Collins S., and Clyma J.A. What changes in the organization of cancer services will improve the outcome for women with ovarian cancer?. Br J Obstet Gynaecol 104 (1997) 135-139
54. Junor E.J., Hole D.J., McNulty L., Mason M., and Young J. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol 106 (1999) 1130-1136
55. Olaitan A., Weeks J., Mocroft A., Smith J., Howe K., and Murdoch J. The surgical management of women with ovarian cancer in the south west of England. Br J Cancer 85 (2001) 1824-1830
56. Tingulstad S., Skjeldestad F.E., and Hagen B. The effect of centralization of primary surgery on survival in ovarian cancer patients. Obstet Gynecol 102 (2003) 499-505
57. McGowan L. Patterns of care in carcinoma of the ovary. Cancer 71 (1993) 628-633
58. Wolfe C.D., Tilling K., and Raju K.S. Management and survival of ovarian cancer patients in South East England. Eur J Cancer 33 (1997) 1835-1840
59. Gillis C.R., Hole D.J., Still R.M., Davis J., and Kaye S.B. Medical audit, cancer registration, and survival in ovarian cancer. Lancet 337 (1991) 611-612
60. Paulsen T., Kjaerheim K., Karen J., Tretli S., and Tropé C. Improved short-term survival for stage IIIc ovarian cancer patients operated at teaching hospitals. Int J Gynecol Cancer 16 suppl. 1 (2006) 11-17
61. National Cancer Guidance Steering Group. Improving outcomes in gynecological cancers: the research evidence (1999), NHS Executive, Department of Health, London
62. Guidelines for Referral to a Gynaecologic Oncologist: Rationale and Benefits. A Special Issue by the Society of Gynecological Oncologists. Gynecol Oncol 78 3 (2000) S7-S8
63. Munkarah A.R., Hallum A.V., Morris M., et al. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol 64 1 (1997) 13-17
64. Vergote I., De Wever I., Tjalma W., Van Gramberen M., Decloedt J., and van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 71 3 (1998) 431-436
65. Vergote I.B., Trimbos J.B., Guthrie D., et al. Results of a randomized trial in 923 patients with high risk early ovarian cancer, comparing adjuvant chemotherapy with no further treatment following surgery. [abstract 802]. J Clin Oncol 20 (2001) 201A